| A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH. (NCT07747090) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2026-12-10 |
| FXS6837 for the Treatment for IgAN Patients（Longterm Study） (NCT07750665) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2026-09-30 |
| QT Interval Effects Study of Oral FXS5626 Tablets (NCT07695779) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2026-08-05 |
| A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC (NCT07562581) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2026-06-01 |
| Phase I Study of FXS0683 in the Treatment of Blood Tumors (NCT07616089) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2026-06-01 |
| Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors (NCT07558200) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2026-05-15 |
| FXS6837 for the Treatment of IgAN Patients (NCT07502638) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2026-03-31 |
| A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU (NCT07552012) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2026-01-29 |
| Phase I Study of FXS887 in the Treatment of Solid Tumors (NCT07345637) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2026-01-05 |
| FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration (NCT07004075) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2025-06-30 |
| Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1 (NCT07024394) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2025-06-12 |
| To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH (NCT05997602) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2023-09-28 |
| FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms (NCT06858618) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2023-08-16 |
| FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (NCT05913037) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2023-06-20 |
| Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC (NCT06569420) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2021-12-31 |
| Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 (NCT04954001) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2021-03-26 |
| Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer. (NCT03944499) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2019-10-11 |
| MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b) (NCT03932253) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2019-03-21 |
| A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML (NCT03690154) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2018-07-23 |